研究者業績
基本情報
経歴
3-
2021年4月 - 現在
-
2020年4月 - 2021年3月
-
- 2019年3月
学歴
1-
1986年4月 - 現在
委員歴
6受賞
13-
2017年5月
-
2016年5月
-
2015年4月
-
2014年5月
-
2013年5月
論文
1237-
Digestion 2025年4月9日INTRODUCTION: Gastrectomy considerably affects the gut microbiome; however, the association between dysbiosis and post-gastrectomy syndrome remains to be explored. This study prospectively explored fecal gut microbiota alterations before and 3 months after gastrectomy, investigating their potential association with weight loss. METHODS: The gut microbiome of 21 patients with gastric cancer scheduled for gastrectomy in April-October 2022 was analyzed using 16S rRNA gene Next-Generation Sequencing. Their microbiome profiles were compared to those of healthy controls. Bacterial taxa demonstrating significant changes were determined using the Linear Discriminant Analysis Effect Size algorithm and further analyzed for their relationship with weight loss in the gastrectomy cohort. RESULTS: Postoperative complications (≥grade 2) were observed in 14.3% of patients. Postoperative weight loss was -10.9%, with the following breakdown: distal (-7.0%), total (-13.5%), and proximal (-14.0%) gastrectomy (P = 0.003). Microbiota analysis demonstrated a significant incline in the abundance of the Streptococcus salivarius group and a decline in Bacteroides uniformis in patients with gastric cancer compared to healthy controls. The S. salivarius group exhibited a further increase, while B. uniformis showed signs of recovery after gastrectomy. Additionally, 5α-reductase gene levels, reported to decrease as several cancers progress, were found to elevate post-surgery. Furthermore, patients experiencing greater weight loss showed a significant reduction in Faecalibacterium prausnitzii levels, while lower serum prealbumin and zinc levels were associated with the abundance of Escherichia coli. CONCLUSION: Gastrectomy significantly alters the gut microbiome. Supporting microbiome health with prebiotics may help alleviate postoperative issues and improve patients' quality of life.
-
DEN open 5(1) e413 2025年4月The new Kyoto guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) provide evidence-based recommendations for the diagnosis and treatment of IPMN. Endoscopic ultrasonography (EUS) is a diagnostic modality with a high spatial resolution that allows detailed observation and obtaining cyst fluid or tissue samples via EUS-guided fine needle aspiration (EUS-FNA). Currently, EUS is an indispensable examination method for the diagnosis of pancreatic diseases. On the other hand, there have been concerns that EUS imaging tends to be highly operator-dependent, and may lack objectivity. Previous guidelines have assigned EUS as an option for patients with worrisome features. However, recent reports indicate that the sensitivity of EUS for the diagnosis of mural nodules (MNs) is more than 90%, comparable or superior to that of contrast-enhanced computed tomography or magnetic resonance cholangiopancreatography. The specific advantages of EUS in the diagnosis of IPMN are: (1) high spatial resolution imaging for the diagnosis of MNs, (2) contrast-enhanced EUS for differentiation of intra-cystic MNs from mucous clots, and (3) pathological diagnosis using EUS-FNA and differential diagnosis of a pancreatic cystic tumor by cystic fluid analysis. In order to utilize EUS in the diagnosis of IPMN, endoscopists are required to have the skills to provide sufficiently objective imaging findings.
-
Journal of hepato-biliary-pancreatic sciences 2025年3月16日PURPOSE: This study aimed to clarify the current treatment status for biliary tract cancers based on data from the National Clinical Database (NCD) in Japan. METHODS: Total 3895 cases of biliary tract cancers registered in the NCD during 2021 were included. We identified the rates of resection, R0 resection, postoperative complications, and incidences of lymph node metastasis for gallbladder carcinoma, perihilar cholangiocarcinoma, distal bile duct carcinoma, and ampullary carcinoma. RESULTS: The number of biliary tract cancers registered in the NCD during 2021 was 3895 (1775 in extrahepatic bile duct carcinoma, 1422 in gallbladder carcinoma, and 698 in ampullary carcinoma). In gallbladder carcinoma, the resection (89.59%) and R0 resection rates (87.99%) were favorable, and the complication rate (6.05%) was lower than that of others. However, the postoperative complication rate could be higher in T3-T4 cases and when extrahepatic bile duct resection was performed concomitantly. Lymph node metastasis was frequently seen in 12.60% at the No. 13a lymph node. In perihilar cholangiocarcinoma, the R0 resection (69.82%) and complication rates (16.75%) were significantly lower and higher, respectively. In distal cholangiocarcinoma and ampullary carcinoma, metastasis was observed in approximately 2% and 10% of the dissected No. 16b1 para-aortic lymph nodes, respectively. In conclusion, although short-term surgical outcomes for biliary tract cancers in Japan might be acceptable, the significantly lower R0 resection and higher complication rates of perihilar cholangiocarcinomas indicate additional challenges for surgeons in the future and should continue to be monitored by the Japanese Society of Hepatobiliary and Pancreatic Surgery.
-
2025年2月21日Feline atopic skin syndrome (FASS) is a chronic inflammatory skin disease characterized by itching and dermatitis. While the relationship between the gut microbiota and atopic dermatitis (AD) has been highlighted, exploring gut-targeted therapies for FASS remain limited. This study aimed to evaluate the effects of a parasynbiotic containing 1-kestose and heat-killed Lactobacillus plantarum FM8 on clinical symptoms and gut microbiota in cats with FASS. Eleven FASS cats were treated with a parasynbiotic containing 1-kestose (400 mg/day) and heat-killed FM8 (2.0 × 1010 CFU/day) for 8 weeks. Clinical symptoms were assessed using the SCORing Feline Allergic Dermatitis (SCORFAD), investigator pruritus score (IPS), and rating of global assessment of improvement (GAI). Fecal microbiota composition was analyzed through 16S rRNA sequencing, with 16 healthy cats serving as controls. Parasynbiotic intervention significantly reduced SCORFAD and IPS scores. GAI scores improved in 10 of 11 cats, with the most severe case maintaining a score of 3. The β-diversity analysis showed no significant differences; however, a trend toward variation was observed between the healthy control cats and the baseline group of FASS cats, as well as between the healthy control cats and post- intervention groups. The abundance of Collinsella stercoris was significantly higher in FASS cats than in healthy controls, and it significantly decreased after parasynbiotic intervention, suggesting potential improvements in gut health and inflammation. This study is the first to demonstrate the potential benefits of parasynbiotic administration in FASS, showing improvements in clinical symptoms and partial modulation of the gut microbiota. These findings highlight parasynbiotic administration as a compelling therapeutic approach for FASS, offering new possibilities for innovative interventions aimed at the gut–skin axis.
-
Microbiology 170(11) 2024年11月21日Recent studies have linked Ruminococcus gnavus to inflammatory bowel disease and Fusobacterium nucleatum to various cancers. Agarooligosaccharides (AOS), derived from the acid hydrolysis of agar, have shown significant inhibitory effects on the growth of R. gnavus and F. nucleatum at concentrations of 0.1 and 0.2%, respectively. RNA sequencing and quantitative reverse-transcription PCR analyses revealed the downregulation of fatty acid biosynthesis genes (fab genes) in these bacteria when exposed to 0.1% AOS. Furthermore, AOS treatment altered the fatty acid composition of R. gnavus cell membranes, increasing medium-chain saturated fatty acids (C8, C10) and C18 fatty acids while reducing long-chain fatty acids (C14, C16). In contrast, no significant growth inhibition was observed in several strains of Bifidobacteria and Lactobacillales at AOS concentrations of 0.2 and 2%, respectively. Co-culture experiments with R. gnavus and Bifidobacterium longum in 0.2% AOS resulted in B. longum dominating the population, constituting over 96% post-incubation. In vivo studies using mice demonstrated a significant reduction in the Lachnospiraceae family, to which R. gnavus belongs, following AOS administration. Quantitative PCR also showed lower levels of the nan gene, potentially associated with immune disorders, in the AOS group. These findings suggest that AOS may introduce a novel concept in prebiotics by selectively inhibiting potentially pathogenic bacteria while preserving beneficial bacteria such as Bifidobacteria and Lactobacillales.
MISC
438-
難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書 197-200 2013年
-
難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書 193-196 2013年
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 248-248 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 422-422 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 82-82 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 364-364 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 82-82 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 83-83 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 428-428 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 340-340 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 369-369 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 354-354 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 353-353 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 390-391 2012年12月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 229-230 2012年12月
-
GASTROENTEROLOGY 142(5) S850-S850 2012年5月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 184-184 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 237-238 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 396-396 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 249-249 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 366-366 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 251-251 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 309-309 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 248-249 2012年4月
-
GASTROINTESTINAL ENDOSCOPY 75(4) 250-250 2012年4月
-
肝胆膵画像 14(1) 10-15 2012年肉眼的胆嚢癌周囲進展度診断は胆道癌取扱い規約によれば,肉眼的胆嚢周囲進展度Tを規定するものとして,S:肉眼的漿膜(腹腔側)浸潤,Hinf:肉眼的肝内直接浸潤,Binf:肉眼的胆管側(肝十二指腸間膜)浸潤,PV:門脈系への浸潤,A:動脈系への浸潤が挙げられている.門脈系への浸潤,動脈系への浸潤に関しては,MD-CTの役割が大きいが,その他の診断に関しては,EUSが優れている.また,第7版TNM分類では,総肝動脈周囲,十二指腸周囲,膵周囲,上腸間膜動脈周囲リンパ節転移は遠隔転移と位置付けられた.(著者抄録)
-
胆と膵 33(7) 565-569 2012年US elastography(EG-US)の登場により、従来の超音波診断(Bモード診断、ドプラ診断)に組織弾性情報が付加された。Real-time Tissue Elastography(RTE)は日本で開発され、世界で最初に製品化されたEG-USであるが、膵疾患の診療ではRTE所見の二つの考え方を理解する必要がある。すなわち、"病変部が周囲組織に比して高硬度あるいは低硬度"という考え方と"病変内の硬度分布が均一あるいは不均一"という考え方であり、前者は膵腫瘍の診断に、後者は膵び漫性疾患の診断に有用と考えられる。当施設では2003年の発売当初から膵疾患に対しRTEを実施し、多くの膵疾患が正常組織と比較して高硬度に描出されることを経験し、その原因が線維化や細胞稠密性、浮腫等の影響であることを病理組織学的に確認した。また病変の種類や進行度によって硬度や均一性/不均一性が異なることも経験し、RTEが膵疾患の鑑別および進行度診断に有用であることも確認している。EG-USの原理および、その所見を正確に理解することで、膵疾患の質的診断能は飛躍的に向上する。EG-USが日常診療に積極的に導入されることを期待する。(著者抄録)
-
肝胆膵治療研究会誌 10(1) 42-50 2012年症例は70歳代、男性。糖尿病にて通院中に黄疸を認め紹介。CT、USにて膵頭部腫瘍に伴う胆管拡張、多発性肺・肝腫瘍および直腸壁の肥厚を認めた。大腸内視鏡検査で直腸癌と診断。ERCP、造影EUS所見が膵癌としては非典型的であったため、確定診断目的にEUS-FNAを施行。病理組織学的に直腸癌の膵転移と診断した。造影EUS、EUS-FNAは転移性膵腫瘍の診断において有用と考える。(著者抄録)
-
消化器内科 55(1) 102-108 2012年超音波内視鏡(EUS)で診断し、12ヵ月以上経過観察できた分岐型膵管内乳頭粘液性腫瘍(IPMN)患者170例(男性95例、女性75例、平均64.7歳)と慢性膵炎患者108例(男性85例、女性23例、平均59.8歳)を対象に、膵癌発生頻度を算出した。分岐型IPMNの平均観察期間は50.4ヵ月で、6例(3.5%)に膵癌発生を認め、Kaplan-Meier法による膵癌発生頻度は5年発生率2.9%であり、標準化膵癌発生比(SIR)は19.6であった。6例中3例は切除不能(癌性腹膜炎2例、多発肝・肺転移1例)の病期で診断された。慢性膵炎の平均観察期間は60.7ヵ月で、3例(2.8%)に膵癌発生を認め、Kaplan-Meier法による膵癌発生頻度は5年発生率2.4%であり、SIRは26.2であった。3例とも膵石を認め、1例は切除不能(血管侵襲+)で、基礎疾患に慢性腎不全を持ち、CTにて経過観察されており、癌性腹水を契機に診断された。
-
膵臓 27(5) 649-655 2012年癌性悪液質は、定型的な栄養サポートでは完全に回復することが困難な進行性の骨格筋量減少を特徴とし、その結果身体機能低下をきたす多因性の症候群と定義されている。その病態は蛋白、エネルギー不足であり、蛋白質代謝の改善が重要である。切除不能進行膵癌では膵内外分泌機能低下にこの癌性悪液質の病態が加わり、著しい体重減少をきたし、その予後をさらに悪化させる。そこで今回我々は切除不能進行膵癌の予後を改善すべく成分栄養療法を施行し、体重安定化に対する効果と予後に対する影響について検討した。成分栄養療法を継続しえた群は、投与12週間後の体重安定化に成功し、生存期間の有意な延長を認めた。切除不能進行膵癌に対する成分栄養療法は、体重安定化を介し予後改善に寄与する有用な治療法の一つとなりうる。(著者抄録)
-
難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書 189-192 2012年
-
難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書 232-233 2012年
-
Gastroenterological Endoscopy (0387-1207)54巻 54(Suppl.1) 1086-1086 2012年
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 26 253-253 2011年10月
所属学協会
15共同研究・競争的資金等の研究課題
11-
日本学術振興会 科学研究費助成事業 2024年4月 - 2029年3月
-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 2018年4月 - 2022年3月